alexa FTY720 Induces Apoptosis Of M2 Subtype Acute Myeloid Leukemia Cells By Targeting Sphingolipid Metabolism And Increasing Endogenous Ceramide Levels | 13546
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

International Conference on Hematology & Blood Disorders
September 23-25, 2013 DoubleTree by Hilton Hotel Raleigh-Durham Airport at RTP, NC, USA

Keqin Kathy Li
Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864.S1.004
Abstract
Purpose: The objective of this study was to evaluate the quality of life (QL) as well as the frequency and severity of depression in patients with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of imatinib mesylate (IMA) treatment. Methods: A detailed analysis of 56 adult patients with CP CML divided into groups according to the length of imatinib treatment was performed as follows: Group A (n=28) ? patients treated for 15 months (median); and Group B (n=28) ? patients treated for 50 months (median). Results: The results from the QL questionnaires found a trend in the improvement in the QL of patients treated with imatinib for 50 months (median) compared to patients treated for 15 months (median) only. However, a statistically significant improvement in the QL of patients with longer imatinib treatment was found only in patients without co-existing invalidity and/or rheumatic disease. Moreover, these two comorbidities increased the level of depressive symptoms in patients with CML during the early period of imatinib therapy. Conclusion: We found a trend in the improvement in the QL of patients with CML in relation to the duration of IMA therapy.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version